Lavie Bio introduces commercial expansion of bio-inoculant Yalos

05-07 | |
Photo: Lavie Bio Ltd.
Photo: Lavie Bio Ltd.

Lavie Bio Ltd., a subsidiary of Evogene Ltd., announced the commercial expansion of its bio-inoculant product, Yalos, to winter wheat. This expansion doubles the potential market for Yalos compared to markets in which Lavie Bio already operates. Winter wheat growers across the US will have access to Yalos for the upcoming 2024-2025 season.

Winter wheat is one of the crucial crops in North America and globally, significantly contributing to the agricultural economy and food supply. The US is expected to produce about 1.28 billion bushels in 2024, with a market value, according to Lavie Bio’s estimation, between $5-$10 billion annually. Introducing Yalos to this market offers substantial potential to capture market share by enhancing crop productivity and sustainability. To date, Lavie Bio has focused on the spring wheat market, along with durum and barley, which together form a smaller market compared to winter wheat.

During the field trials, Yalos has demonstrated enhanced early vigor, biomass, root and shoot development, nutrient availability, and feed quality in winter wheat. Yalos aims to reduce crop abandonment rates and increase farm productivity through advanced biological technologies.

Expanding in more crops

In addition, Lavie Bio is expecting to expand Yalos™ into other key crops, such as soybean and canola, with ongoing field trials in North America and an expected commercial launch in 2025. The US soybean market size is estimated by Lavie Bio at approximately $56.2 billion in 2024.

Lavie Bio Ltd. aims to improve food quality, sustainability, and agriculture productivity through the introduction of microbiome-based ag-biological products. Lavie Bio utilizes a proprietary computational predictive platform, the BDD platform for the discovery, optimization and development of bio-stimulant and bio-pesticide products.

Ed Asscheman Online editor Future Farming